Table 2 Stage of remission, therapy and metastases at study entry
All patients | Group I: lung cancer | Group II: breast cancer | Group III: GI tumors | Group IV: hematol. | Group V: uro-genital | Group VI: CUP | Group VII: others | |
|---|---|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
Stage of remission | ||||||||
ID | 99 (65.6) | 27 (27.3) | 1 (1.1) | 9 (9.1) | 45 (45.5) | 5 (5) | 5 (5) | 7 (7) |
CR | 2 (1.3) | 0 | 0 | 0 | 2 (100) | 0 | 0 | 0 |
PR | 4 (2.6) | 1 (25) | 0 | 0 | 2 (50) | 1(25) | 0 | 0 |
NC | 2 (1.3) | 1 (50) | 0 | 0 | 1 (50) | 0 | 0 | 0 |
PD | 44 (29.1) | 8 (18.2) | 9 (20.5) | 7 (15.9) | 12 (27.3) | 2 (4.5) | 0 | 6 (13.6) |
Metastases | ||||||||
CNS | 16 (10.6) | 8 (50) | 0 | 1 (6.3) | 3 (18.7) | 2 (12.5) | 0 | 2 (12.5) |
Bone | 32 (21.2) | 9 (45) | 6 (18.8) | 1 (3.1) | 8 (25) | 3 (9.4) | 2 (6.3) | 3 (9.4) |
Liver | 17 (11.3) | 2 (11.8) | 2 (11.8) | 8 (47.0) | 3 (17.6) | 2 (11.8) | 0 | 0 |
Lymphatic | 85 (56.3) | 21 (24.1) | 7 (8) | 11 (12.6) | 33 (37.9) | 5 (5.7) | 3 (3.4) | 5 (5.7) |
Therapy (at study entry) | ||||||||
Chemo | 18 (11.9) | 4 (22.2) | 1 (5.6) | 1 (5.6) | 4 (22.2) | 2 (11.1) | 1 (5.6) | 5 (27.7) |
Radiation | 3 (2) | 2 (66.7) | 0 | 0 | 0 | 0 | 0 | 1 (33.3) |
Hormone | 3 (2) | 0 | 1 (33.3) | 0 | 2 (66.7) | 0 | 0 | 0 |